Hemoglobin raffimer

Drug Profile

Hemoglobin raffimer

Alternative Names: Haemoglobin raffimer; Hemolink; Human haemoglobin - Hemosol; Human hemoglobin - Hemosol

Latest Information Update: 11 May 2005

Price : $50

At a glance

  • Originator Hemosol Corp
  • Class Haemoglobins; Trisaccharides
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Anaemia; Hypovolaemia

Most Recent Events

  • 11 May 2005 Discontinued - Phase-II for Hypovolaemia in USA (IV-infusion)
  • 11 May 2005 Discontinued - Phase-II for Anaemia in USA (IV-infusion)
  • 11 May 2005 Discontinued - Preregistration for Hypovolaemia in Canada (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top